Table Of Contents

1. Market Context & Strategic Relevance

 1.1 Opening Context (Why the market matters)

  1.1.1 Why This Market Is Gaining Strategic Attention

  1.1.2 Business Decisions This Report Supports

 1.2 Scope

 1.3 Research & Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Prevention Approach

  2.3.2 Market Size By Product Type

  2.3.3 Market Size By Organ Transplant Type

  2.3.4 Market Size By Patient Type

  2.3.5 Market Size By End User

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO's Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter's) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1. Component & Subsystem Suppliers

  3.4.2. Antibody-mediated Rejection Prevention Product Manufacturers

  3.4.3. Distributors & Channel Partners

  3.4.4. End Users (Hospitals, Transplant Centers, Specialty Clinics)

 3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting

4.1 Transplantation & Patient Treatment Statistics

4.1.1 Annual Solid Organ Transplant Volumes

4.1.2 Antibody-Mediated Rejection Incidence Rates

4.1.3 High-Risk / Sensitized Patient Population Statistics

4.1.4 Rejection-Related Hospitalization & Treatment Rates

4.2 Therapeutic Utilization & Treatment Metrics

4.2.1 Prophylactic vs. Treatment-Oriented Therapy Utilization

4.2.2 Average Treatment Cycles per Patient

4.2.3 Treatment Response & Reversal Rates

4.2.4 Rejection Recurrence & Retreatment Rates

4.3 Clinical & Diagnostic Monitoring Indicators

4.3.1 Donor-Specific Antibody (DSA) Testing Volumes

4.3.2 HLA Antibody Screening & Crossmatch Testing Rates

4.3.3 Post-Transplant Immune Monitoring Frequency

4.3.4 Biomarker & Molecular Rejection Testing Adoption

4.4 Treatment Economics & Healthcare Utilization

4.4.1 Average Cost per AMR Treatment Course

4.4.2 Hospitalization & Intensive Care Resource Utilization

4.4.3 Treatment Duration & Healthcare Resource Requirements

4.4.4 Rehospitalization & Long-Term Graft Management Costs

4.5 Clinical Development & Innovation Indicators

4.5.1 Clinical Trials for AMR Prevention & Treatment

4.5.2 Pipeline Activity by Therapeutic Mechanism

4.5.3 Regulatory Approvals & Product Launch Activity

4.5.4 Novel Immunomodulatory, Complement & B-Cell-Targeted Therapy Development

5. Antibody-mediated Rejection Prevention Market Segmental Analysis & Forecast, By Prevention Approach, 2022–2035, Value (USD Billion)

 5.1 Introduction

 5.2 Desensitization Therapy

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022 – 2035

 5.3 Maintenance Immunosuppression

 5.4 Antibody Removal

 5.5 Complement Inhibition

 5.6 B-cell/Plasma-cell Targeting

 5.7 Others

6. Antibody-mediated Rejection Prevention Market Segmental Analysis & Forecast, By Product Type, 2022–2035, Value (USD Billion)

 6.1 Introduction

 6.2 Monoclonal Antibodies

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 IVIG

 6.4 Immunosuppressive Drugs

 6.5 Complement Inhibitors

 6.6 Plasma Exchange/Apheresis Products

 6.7 Others

7. Antibody-mediated Rejection Prevention Market Segmental Analysis & Forecast, By Organ Transplant Type, 2022–2035, Value (USD Billion)

 7.1 Introduction

 7.2 Kidney

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Heart

 7.4 Lung

 7.5 Liver

 7.6 Other Solid Organs

8. Antibody-mediated Rejection Prevention Market Segmental Analysis & Forecast, By Patient Type, 2022–2035, Value (USD Billion)

 8.1 Introduction

 8.2 Highly Sensitized

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 HLA-Incompatible

 8.4 ABO-Incompatible

 8.5 High-Risk Recipients

 8.6 Others

9. Antibody-mediated Rejection Prevention Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (USD Billion)

 9.1 Introduction

 9.2 Hospitals & Transplant Centers

  9.2.1 Key Trends

  9.2.2 Market Size & Forecast, 2022–2035

 9.3 Specialty Clinics

 9.4 Apheresis & Infusion Centers

 9.5 Diagnostic Laboratories

 9.6 Research Institutions

10. Antibody-mediated Rejection Prevention Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

 10.1 Introduction

 10.2 North America

  10.2.1 Key Trends

  10.2.2 Antibody-mediated Rejection Prevention Market Size & Forecast, By Prevention Approach, 2022–2035

  10.2.3 Antibody-mediated Rejection Prevention Market Size & Forecast, By Product Type, 2022–2035

  10.2.4 Antibody-mediated Rejection Prevention Market Size & Forecast, By Organ Transplant Type, 2022–2035

  10.2.5 Antibody-mediated Rejection Prevention Market Size & Forecast, By Patient Type, 2022–2035

  10.2.6 Antibody-mediated Rejection Prevention Market Size & Forecast, By End User, 2022–2035

  10.2.7 Antibody-mediated Rejection Prevention Market Size & Forecast, By Country, 2022–2035

   10.2.7.1 US

   10.2.7.2 Canada

 10.3 Europe

  10.3.1 Key Trends

  10.3.2 Antibody-mediated Rejection Prevention Market Size & Forecast, By Prevention Approach, 2022–2035

  10.3.3 Antibody-mediated Rejection Prevention Market Size & Forecast, By Product Type, 2022–2035

  10.3.4 Antibody-mediated Rejection Prevention Market Size & Forecast, By Organ Transplant Type, 2022–2035

  10.3.5 Antibody-mediated Rejection Prevention Market Size & Forecast, By Patient Type, 2022–2035

  10.3.6 Antibody-mediated Rejection Prevention Market Size & Forecast, By End User, 2022–2035

  10.3.7 Antibody-mediated Rejection Prevention Market Size & Forecast, By Country, 2022–2035

   10.3.7.1 Germany

   10.3.7.2 France

   10.3.7.3 UK

   10.3.7.4 Italy

   10.3.7.5 Spain

   10.3.7.6 Poland

   10.3.7.7 Russia

   10.3.7.8 Rest of Europe

 10.4 Asia Pacific

  10.4.1 Key Trends

  10.4.2 Antibody-mediated Rejection Prevention Market Size & Forecast, By Prevention Approach, 2022–2035

  10.4.3 Antibody-mediated Rejection Prevention Market Size & Forecast, By Product Type, 2022–2035

  10.4.4 Antibody-mediated Rejection Prevention Market Size & Forecast, By Organ Transplant Type, 2022–2035

  10.4.5 Antibody-mediated Rejection Prevention Market Size & Forecast, By Patient Type, 2022–2035

  10.4.6 Antibody-mediated Rejection Prevention Market Size & Forecast, By End User, 2022–2035

  10.4.7 Antibody-mediated Rejection Prevention Market Size & Forecast, By Country, 2022–2035

   10.4.7.1 China

   10.4.7.2 India

   10.4.7.3 Japan

   10.4.7.4 South Korea

   10.4.7.5 Australia

   10.4.7.6 ASEAN Countries

   10.4.7.7 Rest of Asia Pacific

 10.5 Latin America

  10.5.1 Key Trends

  10.5.2 Antibody-mediated Rejection Prevention Market Size & Forecast, By Prevention Approach, 2022–2035

  10.5.3 Antibody-mediated Rejection Prevention Market Size & Forecast, By Product Type, 2022–2035

  10.5.4 Antibody-mediated Rejection Prevention Market Size & Forecast, By Organ Transplant Type, 2022–2035

  10.5.5 Antibody-mediated Rejection Prevention Market Size & Forecast, By Patient Type, 2022–2035

  10.5.6 Antibody-mediated Rejection Prevention Market Size & Forecast, By End User, 2022–2035

  10.5.7 Antibody-mediated Rejection Prevention Market Size & Forecast, By Country, 2022–2035

   10.5.7.1 Brazil

   10.5.7.2 Argentina

   10.5.7.3 Mexico

   10.5.7.4 Colombia

   10.5.7.5 Rest of Latin America

 10.6 Middle East & Africa

  10.6.1 Key Trends

  10.6.2 Antibody-mediated Rejection Prevention Market Size & Forecast, By Prevention Approach, 2022–2035

  10.6.3 Antibody-mediated Rejection Prevention Market Size & Forecast, By Product Type, 2022–2035

  10.6.4 Antibody-mediated Rejection Prevention Market Size & Forecast, By Organ Transplant Type, 2022–2035

  10.6.5 Antibody-mediated Rejection Prevention Market Size & Forecast, By Patient Type, 2022–2035

  10.6.6 Antibody-mediated Rejection Prevention Market Size & Forecast, By End User, 2022–2035

  10.6.7 Antibody-mediated Rejection Prevention Market Size & Forecast, By Country, 2022–2035

   10.6.7.1 UAE

   10.6.7.2 Saudi Arabia

   10.6.7.3 Qatar

   10.6.7.4 South Africa

   10.6.7.5 Rest of Middle East & Africa

11. Competitive Landscape

 11.1 Key Players' Positioning

 11.2 Competitive Developments

  11.2.1 Year-Wise Strategies & Development, 2022–2026

 11.3 Market Share Analysis, 2025

 11.4 Product/Service & Application Benchmarking

  11.4.1 Product/Service Specifications & Features By Key Players

  11.4.2 Product/Service Heatmap By Key Players

  11.4.3 Application Heatmap By Key Players

 11.5 Industry Start-Up & Innovation Landscape

 11.6 Key Company Profiles

  11.6.1 CSL Behring LLC

   11.6.1.1 Company Overview & Snapshot

   11.6.1.2 Product/Service Portfolio

   11.6.1.3 Key Company Financials

   11.6.1.4 Geographical Presence

   11.6.1.5 SWOT Analysis

  11.6.2 Hansa Biopharma AB

  11.6.3 Omeros Corporation

  11.6.4 Genentech, Inc.

  11.6.5 Alexion, AstraZeneca Rare Disease

  11.6.6 Grifols S.A.

  11.6.7 Takeda Pharmaceutical Company Limited

  11.6.8 Octapharma AG

  11.6.9 argenx SE

  11.6.10 Sanofi

  11.6.11 Novartis AG

  11.6.12 Bristol-Myers Squibb Company

  11.6.13 Veloxis Pharmaceuticals, Inc.

  11.6.14 CareDx, Inc.

  11.6.15 Natera, Inc.

  11.6.16 Terumo BCT, Inc.

  11.6.17 Fresenius Kabi AG

  11.6.18 Miltenyi Biotec B.V. & Co. KG

  11.6.19 Baxter International Inc.

  11.6.20 Novo Nordisk A/S

12. Analyst Recommendations

 12.1 SNS Insider Opportunity Map

 12.2 Industry Low-Hanging Fruit Assessment

 12.3 Market Entry & Growth Strategy

 12.4 Analyst Viewpoint & Suggestions On Market Growth

13. Assumptions

14. Disclaimer

15. Appendix

 15.1 List Of Tables

 15.2 List Of Figures